We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Machine Learning Algorithm Detects Cervical Cancer

By HospiMedica International staff writers
Posted on 24 Jan 2019
A novel colposcope uses an automated visual evaluation (AVE) algorithm to detect cervical cancer from even a single image.

The MobileODT (Tel Aviv, Israel) Enhanced Visual Assessment 3 (EVA3) system is a compact colposcope designed for durability and portability. More...
Features include an ultra-bright powered light source with cross-polarization (to reduce glare); a complementary metal-oxide semiconductor (CMOS) sensor with 13 megapixel resolution; and a powerful 4X optical/16X digital zoom magnification lens that provides a working distance of 225-400 mm. The rechargeable, long-lasting battery provides up to 10 hours of continuous use.

Secure software allows for real-time visualization of the cervix, with enhancement filters that can be applied directly to captured images. Secure online data management allows users to document cases, add annotations, and export the information to an electronic medical record (EMR), simplifying the medical workflow. In addition, a cloud-based information system (EVA Cloud) provides secure access to real time data so as to monitor provider utilization, identify cases reviewed, collect anonymized patient statistics, and enhance quality control and quality improvement opportunities.

The EVA Colposcope is currently used in 29 countries, using smartphone technology and augmented intelligence cervical cancer detection to improve cancer identification. The augmented AVE algorithm can identify problematic lesions with greater reliability than traditional Pap cytology testing, and with a higher level of accuracy than expert human colposcopists, as validated by the U.S. National Cancer Institute (NCI, Rockville, MD, USA) and the National Library of Medicine (Bethesda, MD, USA).

“For this new technology to move out of the laboratory and into healthcare practice, a practical application was needed. The EVA System is the only colposcope on the market ready to deliver AVE at the point-of-care,” said Ariel Beery, CEO of MobileODT. “We are excited by the new AVE algorithm and the promise it holds in fighting cervical cancer. Our team is proud to make available an AVE enabled colposcope to reach more women and save more lives.”

Cervical cancer is the fourth most common cancer in women, with more than 500,000 new cases occurring annually worldwide. The two most common detection methods include the Pap smear, which can be performed by a non-specialist, and colposcopy, which requires visualization of the cervix using a speculum, a colposcope, and a trained professional to administer the test. Colposcopes and people who know how to use them are difficult to find in many low-income regions.

Related Links:
MobileODT


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
12-Channel ECG
CM1200B
New
Medical Examination & Procedure Light
Vega 80
New
Monitor/Defibrillator
Zenix
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The nasal spray is created using the ‘Nano-in-Micron’ technology platform. The micron-sized powder is inhaled and travels along the nose-to-brain pathway, bypassing the blood-brain barrier to deliver the drug directly to the brain (Photo courtesy of The University of Hong Kong

New Nasal Spray Enables Prehospital Neuroprotection in Ischemic Stroke

Ischemic stroke, caused by arterial occlusion in the brain, requires time‑critical intervention to limit neuronal loss. Many patients arrive outside the narrow window for thrombolysis or thrombectomy,... Read more

Surgical Techniques

view channel
Image: MUSA-3 is designed to assist surgeons during open super‑microsurgical procedures by downscaling and stabilizing hand movements (Photo courtesy of Microsure)

Robotic Microsurgery System Gains CE Mark for Clinical Use in Europe

Microsure (Eindhoven, The Netherlands) announced on May 7, 2026 that its MUSA-3 system received CE mark approval, enabling clinical use in Europe. The milestone marks the company’s transition from product... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.